Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes

Data ReadoutpositiveMiniMed Smart MDIPositive

AI Analysis

Summary

MiniMed presented positive clinical evidence from a six-month randomized trial showing that higher responders to MiniMed Smart MDI alerts achieved 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c for people with diabetes.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Six-month randomized trial found 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c among higher responders to MiniMed Smart MDI alerts

Importance:6/10

Sentiment:

0.70

diabetesclinical trialglucose managementmedical deviceTime in RangeHbA1c

Related Companies

$MMED

Read the original article

Published by PR Newswire Pharma on October 5, 2026 11:08 AM

Read Original